Flatiron Health, a healthcare technology company focused on cancer research and part of Roche, partnered with NICE to explore how real-world evidence (RWE) can inform the clinical and cost-effectiveness of health technologies. Together, Flatiron Health and NICE will conduct research using data from Flatiron’s EHR database. The first project, already underway, compares clinical trial-derived survival estimates to real-world survival as noted in electronic health records, and will be used to evaluate opportunities to reduce uncertainty in the estimation of long-term outcomes.
Pall Jonsson, associate director for science policy and research, who is leading the exercise for NICE, said: “We are excited to explore how real-world evidence could be incorporated into our work in the future. Working in this way will test how additional sources of evidence could complement trial and research data in our technology appraisals, especially in helping to resolve uncertainty in the evidence.”
The goal of the collaboration will help NICE expand use of real-world data in service of better outcomes for UK cancer patients.
Read more here. https://flatiron.com/press/press-release/nice-partnership-2020/
(Source: Flatiron Health, Press Release, July 14, 2020)